Expand NKTR Menu
NKTR MENU

NKTR Stock Posts


NKTR #NektarTherapeutics stock increases 2.5% after hours.

After Hours Gainer

NKTR Nektar Therapeutics37.07+0.26+0.7%

After Hours:38.00+0.93 (+2.5%)

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

PRNewswireMon, 9-Feb 4:15 PM
Unusual Option Volume

NKTR Nektar Therapeutics38.61+1.28 (+3.4%)

Nektar Therapeutics trades 3,465 contracts. News: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
View Details...
Unusual Option Volume

NKTR Nektar Therapeutics47.43-1.73 (-3.5%)

Nektar Therapeutics trades 2,252 contracts.
View Details...
Unusual Option Volume

NKTR Nektar Therapeutics50.81-2.49 (-4.7%)

Nektar Therapeutics trades 3,465 contracts. The company has the following event: Conference Call and Webcast to Discuss Results of Phase 2b REZOLVE-AA Trial on Dec 16, 2025. News: REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
View Details...
NKTR #NektarTherapeutics stock declines -5.2% in premarket,

Premarket Decliner

NKTR Nektar Therapeutics53.30-1.40-2.6%

Premarket:50.54-2.76 (-5.2%)

REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata

PRNewswireTue, 16-Dec 7:30 AM
NKTR #NektarTherapeutics stock increases 10.3% after hours.

After Hours Gainer

NKTR Nektar Therapeutics53.30-1.40-2.6%

After Hours:58.80+5.50 (+10.3%)

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

PRNewswireMon, 15-Dec 6:00 PM
Load Earlier Posts
Market Data Delayed 15 Minutes